The Role of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Cancer Stem Cell Signaling
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26167828 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Matthew S Jung und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA. Hauptthemen laut MEDLINE: Receptor Tyrosine Kinase-like Orphan Receptors, Neoplastic Stem Cells, Signal Transduction, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, University of Tennessee Oak Ridge Innovation Institute.
Abstract (Originalsprache)
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a key regulator of cancer stem cell (CSC) biology and signaling. In CSCs, ROR1 acts as a receptor or co-receptor, interacting with non-canonical WNT ligands, and forming complexes with proteins like CD19 and HER2, to activate diverse downstream signaling pathways. ROR1 signaling in CSCs promotes proliferation, maintains stemness, and enhances migration, invasion, and the epithelial-to-mesenchymal transition (EMT). While minimally expressed after embryogenesis, ROR1 is aberrantly upregulated in numerous cancers, including ovarian, breast, pancreatic, and hematologic malignancies. ROR1 overexpression drives tumor progression, resistance to chemotherapies, disease recurrence, and ultimately metastasis. This expression pattern positions ROR1 as a promising target for CSC-specific therapies. High ROR1 expression is consistently linked to aggressive disease and poor patient outcomes. Here, we review ROR1′s role in CSCs and highlight the complex signaling that is observed in the CSC population. Further, we evaluate the gaps in the current understanding of ROR1 signaling in CSCs and describe how ROR1 regulates the associated signaling pathways. Finally, we provide an up-to-date summary of the promising therapeutic strategies targeting ROR1 that overcome conventional cancer treatment limitations. This review highlights the role of ROR1 as a critical, functional driver of CSCs and adverse patient outcomes across various malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
- College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
- Center for Cancer Research, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
- Department of Biochemistry and Cellular and Molecular Biology, College of Arts and Sciences, University of Tennessee, Knoxville, TN 37916, USA.
ORCID-Profile: Matthew S Jung, Won-Young Choi, Wenjing Zhang, Rachel S Perkins
Förderung
- NIGMS NIH HHS
- NIH HHS
- University of Tennessee Oak Ridge Innovation Institute
- NIH
- University of Tennessee Oak Ridge Innovation Institute’s Development and Advancement of Radiopharmaceutical Therapies Convergent Research Initiative
Zitieren
APA
Jung, M. S., Choi, W. Y., Zhang, W., Barrera, F. N., & Perkins, R. S. (2025). The Role of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Cancer Stem Cell Signaling. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26167828
Vancouver
Jung MS, Choi WY, Zhang W, Barrera FN, Perkins RS. The Role of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Cancer Stem Cell Signaling. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26167828
BibTeX
@article{Jung2025,
author = {Jung, Matthew S and Choi, Won-Young and Zhang, Wenjing and Barrera, Francisco N and Perkins, Rachel S},
title = {The Role of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Cancer Stem Cell Signaling},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26167828}
}
EUVIMED